Global Pharma Giants' Financial Performance Overview: Q4 and Full-Year 2023 Results

Apr 29, 2024 18:03 CST Updated 18:03

AbbVie

Innovative Drug Developer

Pfizer

Pharmaceutical R&D Developer

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Merck Group

Pharmaceutical R&D Developer

Bristol-Myers Squibb

Biopharmaceutical and Nutritional Product R&D and Sales

Eli Lilly

Global Pharmaceutical R&D and Production Company

Amgen

Developer of Treatment Drugs for Serious Diseases

Gilead Sciences

Antiviral Drug Developer

Viatris

Generic Drug Manufacturer

Regeneron

Biopharmaceutical Manufacturer

Biogen

New Drug Developer

Vertex

Breakthrough Small Molecule Drug Developer

Moderna

mRNA Therapeutics Developer

Organon

New Drug Research and Development, Manufacturer

Abbott

Diagnostic and pharmaceutical product manufacturers

Roche

Oncology Drug Research, Development, and Manufacturing

AstraZeneca

Biopharmaceutical Manufacturer

Novartis

Drug Development and Manufacturing

Sanofi

Pharmaceutical R&D Developer

GSK

Pharmaceutical R&D Manufacturer

Boehringer Ingelheim

Developer of Innovative Drugs and Therapies

Bayer

Pharmaceutical Product R&D Developer

Sandoz

Global Supplier of Novel Patent Medicines

Fresenius AG

Global Healthcare Service Provider

Grifols

Plasma-Derived and Transfusion Medicine Products Manufacturer

UCB

Biopharmaceutical and Specialty Chemicals Developer

BioNTech

Developer of Novel Biologics

Ipsen

Biopharmaceutical Manufacturer

Takeda

Biopharmaceutical Manufacturer

CSL

Biological Therapy and Influenza Vaccine Developer

Teva

Drug Developer

Astellas Pharma US

A pharmaceutical company

Daiichi-Sankyo

Pharmaceutical R&D Developer

Otsuka

Drug Developer

Eisai

Pharmaceutical Product R&D and Manufacturer

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Fosun Pharmaceutical

Healthcare Industry Group

Sino Biopharm

Pharmaceutical R&D Developer

CSPC

Developer of finished drugs and active pharmaceutical ingredients

SPH

Pharmaceutical R&D and Manufacturing

CR PHARMA COMM

Pharmaceutical Circulation Service Provider

Guangzhou Baiyunshan Pharmaceutical Holdings Company

Integrated Service Provider for Pharmaceuticals and Medical Devices

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source: Xinchangjie

Note: The fiscal year start dates of major companies differ from the calendar year, thus causing inconsistencies between fiscal quarters, years, etc., and the calendar year.

United States

AbbVie Reports Fourth Quarter and Full-Year 2023 ResultsQuarterly net revenue was US$14.3 billion, compared to US$15.1 billion in the same period last year. Quarterly net profit attributable to the company was US$822 million, compared to US$2.473 billion in the same period last year. Net revenue for 2023 was US$54.3 billion, compared to US$58.1 billion in 2022. Full-year net profit attributable to the company was US$4.863 billion, compared to US$11.836 billion in the previous year.

Pfizer Announces Q4 and Full-Year 2023 Financial ResultsRevenue in the fourth quarter was $14.249 billion, compared to $24.29 billion in the same period last year, a year-on-year decrease of 41%. The net loss for the quarter was $3.37 billion, compared to a net profit of $5 billion in the same period last year. Revenue in 2023 was $58.5 billion, compared to $100.3 billion in 2022, a year-on-year decrease of 42%. The net profit for the full year was $2.12 billion, compared to $31.37 billion in 2022, a year-on-year decrease of 93%.

Johnson & Johnson Announces Fourth-Quarter Results for 2023Quarterly sales reached $21.4 billion, a year-over-year increase of 7.3%. Net profit was $4.13 billion, compared to $3.23 billion in the same period last year. By business segment, excluding COVID-19 vaccine sales, pharmaceutical business revenue was $13.68 billion. Johnson & Johnson’s medical device business sales were $7.67 billion, a year-over-year increase of 13.3%.

Merck & Co., Inc. announced its financial results for the fourth quarter and full year of 2023.Fourth Quarter Sales $14.63 Billion, Compared to $13.83 Billion in the Same Period Last Year, a Year-on-Year Increase of 6%. Quarterly Net Loss Attributable to the Company was $1.226 Billion, Compared to a Net Profit of $3.017 Billion in the Same Period Last Year. Pharmaceutical Business Sales were $13.141 Billion, an Increase of 8% Year-on-Year. Animal Health Business Sales were $1.278 Billion, an Increase of 4% Year-on-Year. Full-Year Sales were $60.015 Billion, Compared to $59.283 Billion Last Year. Full-Year Net Profit Attributable to the Company was $365 Million, Compared to $1.4519 Billion Last Year.

Bristol-Myers Squibb announced its Q4 and full-year 2023 financial results.Q4 Total Revenue: $11.477 billion, compared to $11.406 billion in the same period last year. Q4 Net Profit Attributable to the Company: $1.762 billion, compared to $2.022 billion in the same period last year. Full-year Total Revenue: $45 billion, compared to $46.2 billion last year. Full-year Net Profit Attributable to the Company: $8.025 billion, compared to $6.327 billion last year.

Eli Lilly and Company Releases Q4 2023 Financial ReportTotal revenue for the quarter was $9.35 billion, a year-on-year increase of 28%. Net profit was $2.19 billion, compared to $1.94 billion in the same period last year.

Amgen Inc. Announces Fourth Quarter and Full Year 2023 ResultsQ4 Total Revenue: $8.196 Billion, Compared to $6.839 Billion in the Same Period Last Year. Quarterly Net Profit: $767 Million, Compared to $1.616 Billion in the Same Period Last Year, a Year-on-Year Increase of 52%. Total Revenue for 2023: $28.19 Billion, Compared to $26.323 Billion in 2022. Annual Net Profit: $6.717 Billion, Compared to $6.552 Billion the Previous Year.

Gilead Sciences Announces Q4 and Full-Year 2023 Financial ResultsQ4 Total Revenue: $7.115 billion, compared to $7.389 billion in the same period last year. Q4 Net Profit Attributable to the Company: $1.429 billion, compared to $1.64 billion last year. Full-Year Total Revenue: $27.116 billion, compared to $27.281 billion last year. Full-Year Net Profit Attributable to the Company: $5.665 billion, compared to $4.592 billion last year.

Viatris Announces Fourth Quarter and Full Year 2023 Financial Results.Fourth Quarter Total Revenue: $3.837 billion, compared to $3.876 billion in the same period last year. Quarterly Net Loss: $766 million, compared to a net profit of $1.011 billion in the same period last year. Full-Year Total Revenue: $15.427 billion, compared to $16.263 billion the previous year. Full-Year Net Profit: $54.7 million, compared to $2.079 billion the previous year.

Regeneron Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2023 Financial ResultsQ4 Total Revenue: $3.434 billion, compared to $3.414 billion in the same period last year. Q4 Net Profit: $1.16 billion, compared to $1.197 billion in the same period last year. Full-year Total Revenue: $13.117 billion, compared to $12.173 billion last year. Full-year Net Profit: $3.954 billion, compared to $4.338 billion last year.

Biogen Announces Q4 and Full-Year 2023 Financial Results。Q4 Total Revenue: $2.386 Billion, Compared to $2.544 Billion in the Same Period Last Year. Q4 Net Profit Attributable to the Company: $250 Million, Compared to $550 Million Last Year. Full-Year Total Revenue: $9.836 Billion, Compared to $10.173 Billion Last Year. Full-Year Net Profit Attributable to the Company: $1.16 Billion, Compared to $3.05 Billion Last Year.

Vertex Pharmaceuticals Announces Q4 and Full-Year 2023 Financial ResultsQ4 Product Net Revenue: $2.518 billion, compared to $2.303 billion in the same period last year. Q4 Net Profit: $969 million, compared to $819 million in the same period last year. Full-year Product Net Revenue: $9.869 billion, compared to $8.931 billion last year. Full-year Net Profit: $3.62 billion, compared to $3.32 billion last year.

Moderna Announces Fourth Quarter and Full Year 2023 Financial Results.Fourth Quarter Total Revenue: $2.811 Billion, Compared to $5.084 Billion in the Same Period Last Year. Quarterly Net Profit: $217 Million, Compared to $1.465 Billion in the Same Period Last Year. Full-Year Revenue: $6.848 Billion, Compared to $19.263 Billion Last Year. Full-Year Net Loss: $4.714 Billion, Compared to a Net Profit of $8.362 Billion Last Year.

Organon Announces Q4 and Full-Year 2023 Financial ResultsRevenue in the fourth quarter was $1.598 billion, compared to $1.485 billion in the same period last year. Quarterly net profit was $546 million, compared to $108 million in the same period last year. Full-year revenue was $6.263 billion, compared to $6.174 billion last year. Full-year net profit was $1.023 billion, compared to $917 million last year.

Abbott Announces Q4 2023 Financial ResultsQuarterly revenue increased by 1.5% year-over-year to $10.24 billion. By segment, revenue from the medical devices division was $4.44 billion, a year-over-year increase of 17.5%. Revenue from the nutrition business was $2.04 billion, up 12% year-over-year. Diagnostic business revenue was $2.53 billion, down 23% year-over-year. Generic drug business sales were $1.22 billion, a year-over-year increase of 0.5%. Quarterly net profit was $1.594 billion, compared to $1.033 billion in the same period last year.

Europe

Roche announced its financial results for 2023.Full-year group sales were 58.716 billion Swiss francs, compared to 63.281 billion Swiss francs in the previous year. Pharmaceutical business sales were 44.612 billion Swiss francs (approximately 48.9 billion US dollars), with an operating profit of 17.132 billion Swiss francs. Diagnostic business sales were 14.104 billion Swiss francs, with an operating profit of 2.171 billion Swiss francs. The full-year net profit attributable to the company's shareholders was 11.498 billion Swiss francs, compared to 12.421 billion Swiss francs in the same period last year.

AstraZeneca Announces Financial Results for Q4 and Full Year 2023Fourth-quarter revenue was $12.024 billion, compared to $11.207 billion in the same period last year. Quarterly after-tax profit was $959 million, compared to $902 million in the same period last year. Total annual revenue was $45.811 billion, compared to $44.351 billion last year. Annual after-tax profit was $5.961 billion, compared to $3.293 billion last year.

Novartis Reports Q4 and Full-Year 2023 Financial ResultsNet sales in the fourth quarter were US$11.423 billion, an 8% increase year-over-year; quarterly net profit was US$2.638 billion, a 101% increase year-over-year. Full-year net sales reached US$45.4 billion, a 10% increase year-over-year. Net sales in China were US$3.3 billion, a 17% increase year-over-year.

Sanofi Announces Q4 and Full-Year 2023 Financial ResultsFourth Quarter Total Revenue of 10.9 Billion Euros, Up 9.3% Year-on-Year. Full-Year Sales Reached 43.07 Billion Euros, Up 5.3% Year-on-Year. Pharmaceutical Business Revenue was 30.4 Billion Euros (Approximately 32.3 Billion USD), Vaccine Business Revenue was 7.5 Billion Euros (Approximately 7.96 Billion USD), and Consumer Health Business Revenue was 5.2 Billion Euros.

GSK Releases Q4 and Full-Year 2023 Financial ResultsFourth Quarter Revenue £8.052 Billion (Approx. $10 Billion), Compared to £7.376 Billion in the Same Period Last Year. Quarterly Operating Profit £573 Million, Compared to £1.868 Billion in the Same Period Last Year. Quarterly Net Profit Attributable to Shareholders from Continuing Operations £350 Million, Compared to £1.5 Billion in the Same Period Last Year. Full-Year Revenue £30.328 Billion (Approx. $37.7 Billion), Compared to £29.324 Billion Last Year. Full-Year Operating Profit £6.745 Billion, Compared to £6.433 Billion Last Year. Full-Year Net Profit Attributable to Shareholders from Continuing Operations £4.928 Billion, Compared to £4.461 Billion Last Year.

Novo Nordisk Announces 2023 Financial Results.Operating profit for the year increased by 37% in Danish kroner to DKK 102.6 billion, and by 44% at constant exchange rates. Sales grew by 31% to DKK 232.3 billion (approximately USD 33.1 billion), or 36% at constant exchange rates. Semaglutide, Novo Nordisk's star product, generated revenue of DKK 145.811 billion in 2023.

Boehringer Ingelheim Releases Full-Year 2023 Performance Results.In 2023, the group's total annual sales revenue increased by 9.7% year-on-year to 25.611 billion euros. Of this, the total sales revenue of human pharmaceuticals reached 20.774 billion euros (approximately 22.1 billion US dollars), representing a year-on-year increase of 10.3%. The sales revenue of the animal health business was 4.724 billion euros, increasing by 6.9% year-on-year. The total R&D investment for the year increased by 14.2% year-on-year to 5.8 billion euros, accounting for up to 22.5% of sales revenue.

Bayer Group Announces Q4 and Full-Year 2023 Financial ResultsQ4 Group Sales €11.862 Billion, Compared to €12 Billion in the Same Period Last Year. Quarterly Net Profit €1.337 Billion, Compared to €611 Million in the Same Period Last Year. By Business Division, Crop Science Department Sales €5.63 Billion, EBIT Profit €975 Million. Pharmaceuticals Department Sales €4.579 Billion (Approx. $4.86 Billion), EBIT Profit €935 Million. Consumer Health Department Sales €1.578 Billion, EBIT Profit €424 Million. Full-Year Group Sales €47.637 Billion, Compared to €50.739 Billion Last Year. Full-Year Net Loss Attributable to Shareholders €2.941 Billion, Compared to a Net Profit of €4.15 Billion Last Year.

German pharmaceutical and chemical giant Merck Group announced its Q4 and full-year 2023 financial results.Net sales in the fourth quarter were 5.225 billion euros, compared to 5.66 billion euros in the same period last year. Of this, net sales from the life science business were 2.249 billion euros (approximately 2.388 billion US dollars), net sales from the healthcare business were 2.032 billion euros (approximately 2.157 billion US dollars), and net sales from the electronic technology business were 943 million euros. Full-year net sales amounted to 20.993 billion euros, compared to 22.232 billion euros last year. Full-year EBITDA profit was 5.489 billion euros, compared to 6.504 billion euros last year. Full-year net profit after tax was 2.834 billion euros, compared to 3.339 billion euros last year.

Sandoz Announces Q4 and Full-Year 2023 ResultsFourth Quarter Sales $2.543 Billion, Compared to $2.296 Billion in the Same Period Last Year. Full-Year Sales $9.647 Billion, Compared to $9.069 Billion Last Year. Full-Year EBITDA Profit $914 Million, Compared to $1.741 Billion Last Year.

Fresenius Group Announces Q4 and Full-Year 2023 Financial ResultsQuarterly group revenue was 5.678 billion euros, EBITDA profit was 942 million euros, and net profit was 397 million euros. Among them, Fresenius Kabi's revenue was 1.996 billion euros (approximately 2.12 billion US dollars), compared to 2.036 billion euros in the same period last year. Fresenius Helios Clinics' revenue was 3.188 billion euros, compared to 3.031 billion euros in the same period last year. The group's annual revenue was 22.299 billion euros, EBITDA profit was 3.422 billion euros, and net profit was 1.505 billion euros.

Grifols Announces Q4 and Full-Year 2023 Financial ResultsQuarterly revenue was 1.77 billion euros (approximately 1.88 billion US dollars), compared to 1.71 billion euros in the same period last year. Quarterly operating profit (EBIT) was 255 million euros, with a continuing operations profit of 77.73 million euros. Full-year revenue reached 6.59 billion euros (approximately 7 billion US dollars), up from 6.06 billion euros the previous year. Full-year operating profit (EBIT) was 799 million euros, with a continuing operations profit of 181 million euros.

UCB Announces 2023 Financial Results.Full-year revenue was 5.252 billion euros (approximately 5.58 billion US dollars), compared to 5.517 billion euros in the previous year. Full-year adjusted EBITDA profit was 1.349 billion euros, compared to 1.26 billion euros in the previous year. Full-year net profit attributable to the company's shareholders was 343 million euros, compared to 418 million euros in the previous year.

BioNTech Announces Q4 and Full-Year 2023 Financial Results.Total revenue in the fourth quarter was 1.479 billion euros (approximately 1.57 billion US dollars), compared to 4.278 billion euros in the same period last year. Quarterly net profit was 458 million euros, compared to 2.279 billion euros in the same period last year. Total annual revenue was 3.819 billion euros (approximately 4.055 billion US dollars), compared to 17.311 billion euros last year. Annual net profit was 930 million euros, compared to 9.434 billion euros last year.

Biopharmaceutical company Ipsen announced its full-year financial results for 2023.Total annual sales of 3.128 billion euros (approximately 3.32 billion US dollars), compared to 3.025 billion euros in the previous year. Annual core operating profit was 1 billion euros, compared to 1.115 billion euros in the previous year. Annual core consolidated net profit was 766 million euros, compared to 872 million euros in the previous year.

Asia-Pacific

Takeda Pharmaceutical announced its financial results for the first nine months (April-December) of the fiscal year ending December 31, 2023.Revenue for the period was 3212.9 billion yen (approximately 20.8 billion USD), compared to 3071.3 billion yen in the same period last year, representing a year-on-year increase of 4.6%. Operating profit for the period was 224.1 billion yen, compared to 401.9 billion yen in the same period last year, marking a year-on-year decrease of 44.2%. Net profit attributable to the company's owners for the period was 147.1 billion yen, compared to 285.9 billion yen in the same period last year, reflecting a year-on-year decrease of 48.6%.

CSL Group, an Australian biopharmaceutical company, announced its financial results for the first half of the fiscal year ended December 31, 2023.Current Period Group Total Revenue: $8.053 billion, compared to $7.184 billion in the same period last year. Current Period Operating Profit: $3.787 billion, compared to $3.359 billion in the same period last year. Current Period Net Profit Attributable to the Company: $2.017 billion, compared to $1.818 billion in the same period last year. Among these, CSL Behring revenue was $5.238 billion, CSL Seqirus revenue was $1.804 billion, and CSL Vifor revenue was $1.011 billion.

Teva Pharmaceutical Industries Announces Q4 and Full-Year 2023 ResultsNet revenue in the fourth quarter was US$4.457 billion, compared to US$3.884 billion in the same period last year. Net profit attributable to the company for the quarter was US$461 million, compared to a net loss of US$1.3 billion in the same period last year. Full-year net revenue was US$15.846 billion, compared to US$14.925 billion last year. Full-year net loss attributable to the company was US$559 million, compared to a net loss of US$2.446 billion last year.

Astellas Pharma Inc. announced its financial results for the first nine months (April-December) of the fiscal year ending December 31, 2023.Revenue for the period was 1,189.1 billion yen (approximately 7.7 billion USD), compared to 1,164.3 billion yen in the same period last year, representing a year-on-year increase of 2.1%. Operating profit for the period was 149.6 billion yen, compared to 233.7 billion yen in the same period last year, marking a year-on-year decrease of 36%. Net profit for the period was 120.5 billion yen, compared to 188.9 billion yen in the same period last year, reflecting a year-on-year decrease of 36.2%.

Daiichi Sankyo Company, Limited announced its financial results for the first nine months (April-December) of the fiscal year ending December 31, 2023.Revenue for the period was 1173.3 billion yen (approximately 7.6 billion USD), compared to 948.3 billion yen in the same period last year, representing a year-on-year increase of 23.7%. Operating profit for the period was 194.6 billion yen, compared to 127.1 billion yen in the same period last year, marking a year-on-year increase of 53%. Net profit attributable to the company's owners for the period was 163.6 billion yen, compared to 86.7 billion yen in the same period last year, reflecting a year-on-year increase of 88.7%.

Otsuka Holdings Co., Ltd. Announces Financial Results for 2023Full-year revenue was 2018.6 billion yen, compared to 1738.0 billion yen the previous year. Full-year operating profit was 139.6 billion yen, compared to 150.3 billion yen the previous year. Net profit attributable to the company's owners for the full year was 121.6 billion yen, compared to 133.9 billion yen the previous year. Of this, pharmaceutical business revenue was 1364.3 billion yen (approximately 8.83 billion USD), nutrition business revenue was 483.7 billion yen, and consumer goods business revenue was 37.1 billion yen.

Eisai Co., Ltd. Announces Financial Results for the First Nine Months (April-December) of the Fiscal Year Ending December 31, 2023.Revenue for the period was 551.3 billion yen (approximately 3.57 billion USD), compared to 546.2 billion yen in the same period last year, representing a year-on-year increase of 0.9%. Operating profit for the period was 37.537 billion yen, compared to 13.823 billion yen in the same period last year, marking a year-on-year increase of 172%. Net profit attributable to owners of the parent company for the period was 29.1 billion yen, compared to 39.1 billion yen in the same period last year, reflecting a year-on-year decrease of 25.6%.

China

Hengrui Pharma Releases 2023 Annual Report.The company achieved operating revenue of 22.82 billion yuan, a year-on-year increase of 7.26%, and net profit attributable to shareholders of the listed company was 4.302 billion yuan, a year-on-year increase of 10.14%. The non-recurring net profit attributable to shareholders of the listed company was 4.141 billion yuan, a year-on-year increase of 21.46%. In 2023, the company's innovative drug revenue reached 10.637 billion yuan (including tax, excluding external licensing revenue). Despite facing impacts from changes in the external environment, product price reductions, and market access difficulties, it still achieved a year-on-year growth of 22.1%.

Hansoh Pharma Releases 2023 Annual Results.Revenue reached RMB 10.104 billion during the reporting period, representing an increase of approximately 7.7% compared to the same period last year. Net profit amounted to RMB 3.278 billion, marking a year-on-year growth of about 26.9%. In 2023, revenue from Hansoh Pharma's innovative drugs and collaboration products reached approximately RMB 6.865 billion, reflecting a year-on-year increase of around 37.1%. In 2023, Hansoh Pharma's research and development expenditure was approximately RMB 2.097 billion, up by about 23.8% year-on-year, with its proportion of total revenue increasing to 20.8%.

Fosun Pharmaceutical Releases 2023 Annual Report.Revenue for the year reached 41.4 billion yuan, a year-on-year decrease of 5.81%; net profit attributable to shareholders of the listed company was 2.386 billion yuan, a year-on-year decrease of 36.04%. In 2023, Fosun Pharmaceutical's pharmaceutical business achieved revenue of 30.222 billion yuan, its medical device and medical diagnostic business achieved revenue of 4.39 billion yuan, and its healthcare services business achieved revenue of 6.672 billion yuan, a year-on-year increase of 9.74%.

Sino Biopharm Releases 2023 Annual Results.Annual revenue reached RMB 26.2 billion, representing a year-on-year increase of 0.7%. Adjusted net profit attributable to shareholders was RMB 2.59 billion, up 1.5% year-on-year. Revenue from innovative products reached RMB 9.89 billion, marking a year-on-year increase of 13.3%. R&D investment in 2023 amounted to RMB 4.4 billion, accounting for 16.8% of total revenue.

CSPC Pharmaceutical Group Limited Discloses Full-Year 2023 Performance.The company achieved revenue of 31.45 billion yuan, a year-on-year increase of 1.7%; net profit reached 5.87 billion yuan, a year-on-year decrease of 3.6%. Of this, finished drug products generated revenue of 25.637 billion yuan, a year-on-year increase of 4.6%, while raw material products and functional foods as well as other segments achieved revenues of 3.641 billion yuan and 2.172 billion yuan respectively, representing year-on-year decreases of 9.7% and 8.9%, respectively.

SPH Releases 2023 Annual ReportIn 2023, the company achieved a revenue of 260.295 billion yuan, representing a year-on-year increase of 12.21%. Of this, the pharmaceuticals industry generated sales revenue of 26.257 billion yuan, marking a year-on-year decrease of 1.87%, while the pharmaceuticals commerce segment achieved sales revenue of 234.038 billion yuan, reflecting a year-on-year growth of 14.04%. Due to the impact of one-time gains and losses, net profit attributable to shareholders was 3.768 billion yuan, showing a year-on-year decrease of 32.92%. Excluding the impact of one-time gains and losses, net profit attributable to shareholders amounted to 4.919 billion yuan, with a year-on-year increase of 2.99%.

CR PHARMA COMM Announces 2023 Financial ResultsRevenue in 2023 was RMB 244.7 billion, compared to RMB 218.2 billion in 2022. Profit attributable to the company's equity holders was RMB 3.854 billion, compared to RMB 3.5 billion in the previous year. During the reporting period, CR PHARMA COMM's traditional Chinese medicine business segment achieved revenue of RMB 21.593 billion; its chemical pharmaceuticals business achieved revenue of RMB 17.032 billion; its biopharmaceuticals business achieved revenue of RMB 2.136 billion; and its nutritional health products and other businesses achieved revenue of RMB 2.704 billion. The group's pharmaceutical distribution business achieved segment revenue of RMB 202.3 billion, representing a year-on-year increase of 11.4%. Pharmaceutical retail operations recorded revenue of RMB 9.578 billion, representing a year-on-year increase of 26.2%.

Guangzhou Baiyunshan Pharmaceutical Holdings Company (Guangzhou Pharmaceuticals) Discloses Q4 and Full-Year 2023 Performance.Q4 Revenue reached 17.33 billion yuan, with a net profit attributable to shareholders of 264 million yuan. Full-year revenue amounted to 75.515 billion yuan, representing a 6.68% increase over the previous year. The full-year net profit attributable to shareholders was 4.056 billion yuan, marking a year-on-year growth of 2.25%. Among this, revenue from traditional Chinese medicine business was 6.27 billion yuan, while revenue from chemical pharmaceuticals was 4.618 billion yuan.

END

The King of M&A, Investing in the Largest Single Project in China

Just now, the Surui® robot was ranked on this important list.

Mindray: Joining Hands to Create a Blueprint for the Development of Chinese Surgery

After $17 Billion Acquisition, Medical Device Giant Cuts Jobs and Closes Plants Again

FDA Warning: Imaging Giant's China Factory Violates Regulations

MFA Responds: EU Launches Investigation into Equipment Procurement in China

For the First Time, Medtronic Appoints This Senior Executive

Just now, the chairman of Johnson & Johnson China resigned.

Imaging Unicorn, Listed Today

First in Asia, Medical Device Giant Invests 1.2 Billion in Shanghai

World's First: Simultaneous Surgery Completed by Dual Robots

BusinessBusiness cooperation email: qxzj@landianyiliao.com